Digoxin: Dosing, Therapeutic Range and Toxicity Management

Definition and Pathophysiology

Digoxin, a cardiac glycoside first described by William Withering in 1775, is the oldest pharmacologic agent in the heart failure armamentarium. Its use has declined over time due to the advent of more efficacious agents with wider therapeutic-to-toxic windows, and its routine use in adult patients is generally discouraged. However, it retains a specific niche in contemporary cardiovascular pharmacotherapy.

The pharmacologic foundation of digoxin lies in its inhibition of the Na+-K+-ATPase, the enzymatic equivalent of the cellular sodium pump. Digoxin binds reversibly to a specific high-affinity site on the extracytoplasmic face of the alpha subunit of the Na+-K+-ATPase. This binding is entropically driven and preferentially occurs after the phosphorylation of a beta-aspartate on the cytoplasmic face of the alpha subunit, thereby stabilizing the E2P conformation of the enzyme. By inhibiting this pump, digoxin affects multiple cellular processes critical to cardiac myocyte function, ultimately exerting a mild positive inotropic effect.

Beyond its direct cellular actions, digoxin exerts significant systemic effects via the autonomic nervous system. It attenuates carotid sinus baroreceptor activity and acts centrally and peripherally to enhance vagal tone. These sympatho-inhibitory effects decrease serum norepinephrine levels, plasma renin levels, and potentially aldosterone levels.

Clinical Presentation and Symptoms

In the management of heart failure, digoxin improves hemodynamics without increasing heart rate or decreasing blood pressure, making it a consideration for patients with low blood pressure secondary to a low cardiac output. Its primary clinical utility in contemporary practice is late-line therapy for patients who remain profoundly symptomatic despite optimal neurohormonal blockade and adequate volume control. It is also utilized for ventricular rate control in atrial fibrillation, particularly when other therapeutic options cannot be pursued.

Patients receiving digoxin may present with symptoms of digitalis toxicity, which manifests across multiple organ systems. Non-cardiac symptoms include headache, nausea, vomiting, generalized malaise, and visual disturbances such as altered color perception and halo vision. Cardiac toxicity presents as various arrhythmias, ranging from bradycardias related to enhanced vagal effect to life-threatening tachyarrhythmias.

Evaluation and Physical Examination

Physical examination of a patient on digoxin therapy should focus on identifying signs of heart failure decompensation, which may indicate inadequate rate control or worsening hemodynamics, and signs of digoxin toxicity. Toxicity can manifest as sinus bradycardia or sinus arrest, atrioventricular (AV) node block, and junctional, fascicular, or ventricular tachyarrhythmias. Patients may also exhibit neurological or visual symptoms consistent with digitalis toxicity.

Several underlying conditions increase a patient's sensitivity to digitalis-related arrhythmias. The clinician must evaluate for the presence of worsening renal function, advanced age, hypokalemia, chronic lung disease, hypothyroidism, and amyloidosis. Furthermore, ongoing ischemia, hypomagnesemia, and moderate to severe renal impairment increase the likelihood of digitalis intoxication even at therapeutic doses.

Diagnostics

Electrocardiography and Electrophysiology

Electrocardiographic evaluation of patients receiving digoxin reveals specific electrophysiologic profiles. Digoxin's autonomic actions largely slow the sinus node discharge rate, shorten atrial refractoriness, and prolong AV nodal refractoriness. Its electrophysiologic effects on the His-Purkinje system and ventricular muscle are minimal, except in cases of toxic concentrations.

In most patients, the sinus rate and P wave duration are minimally changed. The sinus rate may decrease in heart failure patients whose left ventricular performance is improved by the drug, but individuals with significant underlying sinus node disease may experience slower sinus rates or even sinus arrest. The PR interval is generally unchanged, except in patients with underlying AV node disease. The QRS and QT intervals are unaffected. Characteristic ST and T wave abnormalities are commonly seen with digoxin use but do not represent toxicity.

When toxicity is suspected, electrocardiographic monitoring is crucial. Digitalis-related arrhythmias include bradycardias driven by enhanced vagal effect (e.g., sinus bradycardia, AV node block) and tachyarrhythmias caused by delayed afterdepolarization (DAD)-mediated triggered activity, including junctional, fascicular, or ventricular tachycardias.

Biomarkers and Laboratory Findings

Therapeutic drug monitoring via serum digoxin levels is a cornerstone of management due to the drug's extremely low therapeutic index and significant pharmacokinetic variability. The optimal trough digoxin serum level is 0.5 to 1 ng/mL. This range is derived from the dose ranges for positive inotropic effects, neuohormonal inhibition, and mortality data from the DIG trial. For patients with atrial fibrillation and heart failure, serum concentrations should also be maintained in this low range to control ventricular rate response, and levels should generally be kept <1.2 ng/mL.

Blood samples for serum digoxin levels must be collected after the drug distribution phase. Digoxin has a prolonged distribution phase, requiring samples to be collected at least 6 to 8 hours following the last dose, though 12 or more hours is preferable. Samples should generally be obtained just before the next dose, at steady state, to determine the minimum plasma concentration during the dosing interval. The exception to trough sampling is when toxicity is suspected; in this scenario, monitoring is best accomplished at the time of anticipated peak drug concentrations.

Routine monitoring of digoxin levels is not warranted in patients whose ventricular rate is controlled during atrial fibrillation and who have no symptoms of toxicity. However, monitoring is useful to ensure compliance, confirm suspected toxicity, or manage unstable renal function and potential drug interactions.

Treatment and Management

Pharmacokinetics and Dosing

Digoxin is approximately 25% protein bound in plasma, has a large volume of distribution (4-7 L/kg), and crosses both the blood-brain barrier and the placenta. It is eliminated primarily by renal mechanisms via glomerular filtration and tubular secretion. Tubular excretion occurs through the energy-dependent membrane-bound efflux pump P-glycoprotein, which is modulated by many other drugs. Digoxin is largely excreted in the urine unchanged, with a clearance rate proportional to the glomerular filtration rate, resulting in the excretion of approximately one-third of body stores daily. The serum half-life is 36 to 48 hours in patients with normal or near-normal renal function, permitting once-daily or every-other-day dosing.

Oral absorption varies by preparation; tablet forms are 60% to 75% (or up to 80% for Lanoxin) absorbed, whereas encapsulated gel forms are almost completely absorbed. Concurrent ingestion of cholestyramine or antacid preparations decreases absorption. Intravenous administration yields some electrophysiologic effect within minutes, with a peak effect occurring after 1.5 to 3 hours. After oral dosing, the peak effect occurs in 4 to 6 hours. Intramuscular administration is absorbed unpredictably, causes local pain, and is not recommended.

Dosing must be individualized based on clinical indications, renal function, body size, and the presence of coadministered drugs causing pharmacokinetic interactions. Nomograms should not be used in patients with heart failure due to the narrow therapeutic index and the unpredictability of numerous pharmacokinetic factors.

Acute and Long-Term Strategies

In acute settings, digoxin can be administered intravenously to slow the ventricular rate during atrial fibrillation and atrial flutter. An initial intravenous bolus of 0.5 mg should be given slowly over at least 15 minutes to avoid systemic vasoconstrictor responses. This initial bolus should be followed by an oral or intravenous dose of 0.25 mg at least 12 hours after the initial dose. Acute loading doses can range from 0.5 to 1.0 mg orally or intravenously, or 0.75 to 1.25 mg orally over a 24-hour period in three to four divided doses (with intravenous doses being 25% lower).

For chronic maintenance, oral dosing typically ranges from 0.125 to 0.25 mg daily as a single dose. For the great majority of patients, particularly the elderly, those with impaired renal function, and those with a low lean body mass, the dose should be 0.125 mg daily. Some patients undergoing renal dialysis may require as little as 0.125 mg every other day, whereas young patients may require as much as 0.5 mg daily. Higher doses (e.g., >0.25 mg daily) are rarely used and are not recommended for the management of heart failure patients in sinus rhythm or atrial fibrillation. In the absence of loading doses, nearly steady-state blood levels are achieved in four to five half-lives, or about 1 week after initiation of maintenance therapy if normal renal function is present. Trough levels should be measured 1 to 2 weeks after initiation and at frequent intervals (every 1-3 months) thereafter.

Management of Toxicity

Therapy for most digitalis-induced bradycardias consists of withdrawal of digoxin. Atropine or temporary pacing may be required in symptomatic patients. Phenytoin can be utilized to control atrial tachyarrhythmias, whereas lidocaine is successful in treating infranodal tachycardias. Electrical direct current (DC) cardioversion should be performed only when absolutely necessary in a digitalis-toxic patient, as it can precipitate life-threatening ventricular tachycardia or ventricular fibrillation that is difficult to control.

For life-threatening digoxin or digitoxin toxicity, antidigoxin immunotherapy can reverse the toxicity. Purified Fab fragments from digoxin-specific antisera are administered intravenously in saline over 30 to 60 minutes. The dose is calculated using a simple formula based on either the estimated dose of drug ingested or the total body digoxin burden. Extracellular potassium can promote dephosphorylation at the binding site, decreasing cardiac glycoside binding affinity, which explains why increased extracellular potassium tends to reverse some manifestations of digitalis toxicity.

Drugs and Practical Considerations

Guideline Recommendations

Guidelines reflect the nuanced, late-line position of digoxin in contemporary therapy. The 2022 ACC/AHA/HFSA guidelines recommend the use of digoxin in patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic on guideline-directed medical therapy (GDMT) to decrease hospitalizations (Class 2b recommendation). It may also be considered in patients who are intolerant to GDMT.

For atrial fibrillation, digoxin should be considered in patients with a rapid ventricular rate (>110 beats per minute) despite beta-blockers. It can be administered intravenously in boluses of 0.25 to 0.5 mg if not previously used. In patients with comorbidities such as chronic kidney disease, factors affecting digoxin metabolism, or in the elderly, serum concentrations must be measured.

The Digitalis Investigation Group (DIG) trial, which randomized 6800 patients with NYHA Class I through IV heart failure and an LVEF <45% to digoxin or placebo, demonstrated a neutral effect on mortality. However, treatment reduced hospitalizations, including 30-day readmissions for heart failure, and favorably affected the combined endpoints of death or hospitalization due to worsening heart failure. Importantly, the trial revealed that mortality was directly related to the digoxin serum level, and treatment resulted in a higher mortality rate and hospitalizations in women than in men. The benefit of digoxin on contemporary GDMT remains unclear, as most studies preceded the use of beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.

Prognosis and Follow-Up

The prognosis of patients on digoxin is heavily dependent on maintaining strict therapeutic drug monitoring. Low doses are sufficient to achieve potentially beneficial outcomes, and higher doses breach the therapeutic safety index. While digoxin levels should be checked to minimize toxicity and doses reduced for high levels, no dose adjustment is made for low levels if the patient is stable.

Follow-up requires monitoring renal function, as digoxin clearance parallels glomerular filtration rate. In cases of prerenal azotemia with an elevated blood urea nitrogen/creatinine ratio, some filtered digoxin undergoes tubular reabsorption. Furthermore, in heart failure patients, increased cardiac output and renal blood flow in response to vasodilators or sympathomimetic agents may increase renal digoxin clearance, necessitating dosage adjustment.

Digitoxin is a potential alternative to digoxin, particularly in patients with reduced renal function, as its use in heart failure and sinus rhythm is currently being investigated in randomized placebo-controlled trials. Recent data from the DIGIT-HF trial indicated that digitoxin led to a significantly decreased risk of death from any cause and heart failure hospitalization among NYHA class III-IV HFrEF patients treated with contemporary GDMT compared to placebo.